Association of Lower Plasma Fetuin-A Levels with Peripheral Arterial Disease in Type-2 Diabetes

Luis H. Eraso MD¹, Naeema Ginwala, BA¹, Atif N. Qasim MD¹, Nehal N. Mehta MD¹, Rachel Dlugash¹, Shiv Kapoor PhD¹, Stanley Schwartz MD², Mark Schutta MD², Nayyar Iqbal MD², Emile R. Mohler III MD¹,³, Muredach P. Reilly MB¹,²,³

The Cardiovascular Institute¹, the Institute of Diabetes Obesity and Metabolism² and the Institute for Translational Medicine and Therapeutics³, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA.

Address for Correspondence:
Muredach P. Reilly
E-mail: muredach@mail.med.upenn.edu

Additional information for this article can be found in an online appendix at http://care.diabetesjournals.org

Submitted 17 August 2009 and accepted 28 October 2009.

This is an uncopyedited electronic version of an article accepted for publication in Diabetes Care. The American Diabetes Association, publisher of Diabetes Care, is not responsible for any errors or omissions in this version of the manuscript or any version derived from it by third parties. The definitive publisher-authenticated version will be available in a future issue of Diabetes Care in print and online at http://care.diabetesjournals.org.
Objectives: Fetuin-A is an inhibitor of vascular calcification and a mediator of insulin resistance. This study evaluated the association of low plasma fetuin-A and peripheral arterial disease (PAD).

Research Design and Methods: A total of 738 individuals with type-2 diabetes (mean age 58.7 years, 37.1% female) without known cardiovascular or kidney disease were included in this cross-sectional analysis.

Results: Subjects with PAD had a significantly lower fetuin-A (264.3 vs. 293.4 ng/dl, P<0.001). In multivariable analysis, a one standard deviation decrease in fetuin-A increased the odds of PAD (OR 1.6, p=0.02). Subgroup analysis revealed an increased odds even in subjects with eGFR >80 (OR 1.9, p=0.05) or hsCRP <3 mg/dl (OR=2.7, p=0.002).

Conclusion: Lower circulating fetuin-A is associated with PAD in type-2 diabetes beyond traditional and novel cardiovascular risk factors. Our findings suggest a potentially unique role for fetuin-A deficiency as a biomarker of PAD in patients with type-2 diabetes.
Individually with type-2 diabetes have an increased risk for infra-inguinal arterial involvement, microvascular disease, and a higher tendency to develop intimal atherosclerotic calcification as well as medial arterial calcification. Despite advances in the understanding of the pathophysiology of atherosclerosis, however, limited data is available on the determinants of the distinct patterns of peripheral arterial disease (PAD) observed in type-2 diabetes.

Based on the relationship of fetuin-A deficiency with peripheral vascular calcification in experimental models, we hypothesized that low fetuin-A levels in type-2 diabetes are associated with PAD independent of the presence of kidney disease or cardiovascular disease (CVD).

**RESEARCH DESIGN AND METHODS**

**Study Participants:** The Penn Diabetes Heart Study (PDHS) is an ongoing, cross-sectional study of individuals with type-2 diabetes (35 to 75 years) without clinical evidence of CVD (myocardial infarction, coronary revascularization or angiographic disease, positive stress test, clinical peripheral arterial disease or peripheral arterial revascularization, stroke or transient ischemic attack). Subjects with type-1 diabetes and creatinine > 2.5 mg/dL are excluded. The University of Pennsylvania Institutional Review Board approved the study protocol, and all subjects gave written informed consent.

**Evaluated Parameters:** The ankle brachial index (ABI) was calculated dividing the average of the ankle pressures by the highest brachial pressure. An ABI < 0.9 in either leg was used to define PAD. Participants with an ABI > 1.4 (N=13) reflecting non-compressible arteries were excluded. Each subject had the glomerular filtration rate (eGFR) calculated based on the abbreviated Modification of Diet in Renal Disease study equation. Plasma levels of fetuin-A (4.3% and 10.2% intra-assay and inter-assay coefficient of variation) were measured by ELISA (Biovendor laboratory Medicine, Czech Republic). High sensitivity CRP (hsCRP) was measured by immunoturbidimetric assay (Wako Ltd., Osaka Japan).

**Statistical Analysis:** Categorical variables were compared with an χ² test and/or Fisher exact test. Student t test was used for normal continuous variables, and the Kruskal Wallis test for non-normal distributed variables. All non-normal distributed variables were log transformed for the analysis. The association between a one standard deviation (SD) change in fetuin-A and PAD was examined using unadjusted and multivariable adjusted logistic regression models as described in Table 1. A p<0.05 was considered statistically significant. Analyses were performed on Stata 10.0 software (Stata Corp, College Station, TX).

**RESULTS**

Among the 738 subjects in the study sample, PAD prevalence was 5.1%, the mean age was 58.7 (±9.3) years, 37.1% were female, 63.2% Caucasians and 32.1% African Americans. The median fetuin-A level was 292.4 ng/ml (IQR=115.5). Individuals with PAD had a significantly lower fetuin-A level compared to individuals without PAD (269.3 vs. 293.4, p<0.001). PAD subjects were older and had a higher proportion of African Americans. No significant differences were noted in other cardiovascular risk factors, metabolic syndrome, kidney function, inflammation, body mass index, serum albumin (the only surrogate marker of liver function collected on PDHS) or medication use. Fetuin-A levels decreased consistently (p for trend <0.02) across ABI clinically relevant cut points (<0.7, 0.7 to 0.9, 0.9 to 1.1, 1.1 to 1.4). (See Supplemental Figure 1 in the online appendix at http://care.diabetesjournals.org.)
The odds of PAD were significantly increased for each SD decrease in fetuin-A (OR=1.6, 95% CI 1.1-2.3, p=0.001) and the association persisted in incremental models that adjusted fully for age, gender, race, kidney function, cardiovascular risk factors, medication use and hsCRP (OR=1.6, 95% CI 1.05-2.5, p=0.03) (Table 1). A similar trend was noted among subjects with eGFR >80 mL/min/1.73 m² (OR 1.9, 1.0-3.4, p=0.05) suggesting our findings were not confounded by the presence of moderate kidney disease. Finally, in a fully adjusted subgroup analysis, participants with hsCRP levels <3 mg/dl (n=460) had higher odds of PAD (OR=2.6, 95% CI 1.4-5.0; p=0.002), whereas subjects with high hsCRP levels (≥3 mg/dl; n=234) did not (OR=0.82, 95%CI 0.4-1.6; p=0.59).

CONCLUSIONS

Low levels of fetuin-A have been linked to medial arterial calcification and flow limiting aortic stenosis in humans 8, 9. In this study, we demonstrate that lower levels of fetuin-A are associated with PAD in subjects with type-2 diabetes. To our knowledge, this is the first study to report such relationship in the absence of advanced kidney disease or prevalent CVD. Notably, in analysis stratified by CDC/AHA-defined hsCRP risk strata10, fetuin-A conferred increased odds of PAD in subjects with hsCRP < 3 mg/dl and also in participants with IL-6 levels below the median (data not shown). This is consistent with studies reporting an increased CVD risk mortality with fetuin-A deficiency independent of hsCRP and IL-6 11, and points to a unique role for this negative acute phase protein as a biomarker of PAD beyond traditional and novel cardiovascular risk factors.

Remarkably, animal models appear to track with our clinical observations. In mice lacking the fetuin-A gene the aorta was found to be spared of calcification and fibrosis, whereas peripheral vessels in the skin and kidney showed evidence of extensive calcification 2, and the small artery involvement preceded the renal impairment 4. However, in the absence of direct imaging data, we are unable to define the type of vascular phenotype (intimal calcification or medial calcification) that account for the observed association. An ABI of less than 0.9 is 95% sensitive and 99% specific for a stenotic lesion (>50%)12. Therefore, we assume that some degree of eccentric atherosclerotic calcification contributes to the association observed while acknowledging that multiple types of vascular calcification may coexist in type-2 diabetes13.

Non Alcoholic Liver Disease (NALD) and other phenotypes related to insulin resistance, including type-2 diabetes mellitus14, are associated with higher levels of fetuin-A14. We controlled for most potential confounding factors and found no attenuation of the inverse association of fetuin-A with PAD. In particular, due to this inverse relationship, a significant confounding effect was not expected by any condition associated with high fetuin-A levels. Finally, our study is limited by cross-sectional design which limits causal inferences.

In summary, low plasma fetuin-A levels are associated with PAD in type-2 diabetes independent of traditional and contemporary risk factors. Our findings suggest a unique role for fetuin-A deficiency as a biomarker of PAD in the setting of type-2 diabetes.

ACKNOWLEDGEMENTS

This work was supported by a Clinical and Translational Science Award (UL1-RR024134), a Diabetes and Endocrinology Research Center Award (P20 DK019525), a RO1 HL-073278 and a P50 HL-083799-SCCOR to MPR. LHE is supported by a NHLBI-K12 Career Development Award (K12-HL083772).
REFERENCES


**Table 1. Association between Fetuin-A and Peripheral Arterial Disease**

<table>
<thead>
<tr>
<th></th>
<th>Odds of PAD</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Unadjusted</td>
<td>1.6 (1.1-2.3)</td>
<td>0.01</td>
</tr>
<tr>
<td>Model 1</td>
<td>1.6 (1.08-2.2)</td>
<td>0.02</td>
</tr>
<tr>
<td>Model 2</td>
<td>1.8 (1.1-2.6)</td>
<td>0.007</td>
</tr>
<tr>
<td>Model 3</td>
<td>1.6 (1.05-2.5)</td>
<td>0.03</td>
</tr>
</tbody>
</table>

Odds ratio and 95% confidence intervals were obtained by logistic regression model
Model 1: Adjusted for Age, Gender and Race, eGFR
Model 2: Model 1 + Smoking, Hypertension, Hypercholesterolemia, Metabolic Syndrome, HbA1c, Framingham Risk Score (%) and Medications (ACE inhibitors, aspirin, statins, insulin, metformin, sulfonylurea, thiazolidindione).
Model 3: Model 2 + hsCRP